Last updated: 3 December 2020 at 9:48pm EST

Ivan Gergel Net Worth




The estimated Net Worth of Ivan P. Gergel is at least $468 Thousand dollars as of 29 September 2017. Ivan Gergel owns over 100,000 units of NextTrip stock worth over $280,095 and over the last 11 years he sold NTRP stock worth over $188,073. In addition, he makes $0 as Director at NextTrip.

Ivan Gergel NTRP stock SEC Form 4 insiders trading

Ivan has made over 14 trades of the NextTrip stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of NTRP stock worth $1,104,000 on 29 September 2017.

The largest trade he's ever made was exercising 100,000 units of NextTrip stock on 29 September 2017 worth over $1,104,000. On average, Ivan trades about 9,049 units every 41 days since 2014. As of 29 September 2017 he still owns at least 98,279 units of NextTrip stock.

You can see the complete history of Ivan Gergel stock trades at the bottom of the page.





Ivan Gergel biography

Ivan Gergel is the Director at NextTrip.



What's Ivan Gergel's mailing address?

Ivan's mailing address filed with the SEC is C/O NEUROTROPE, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036.

Insiders trading at NextTrip

Over the last 10 years, insiders at NextTrip have traded over $2,644 worth of NextTrip stock and bought 245,000 units worth $210,900 . The most active insiders traders include Bruce Bernstein, Ivan P. Gergel, and Andrew D Perlman. On average, NextTrip executives and independent directors trade stock every 180 days with the average trade being worth of $69,913. The most recent stock trade was executed by Jonathan Schechter on 30 October 2020, trading 25,000 units of NTRP stock currently worth $24,500.



What does NextTrip do?

sigma labs, inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3d printing, and other advanced manufacturing technologies. sigma labs is pioneering the commercialization of in-process metallurgical and geometric quality assurance monitoring technology. printrite3d® with its software modules inspect™, contour™ and analytics™ is the industry's first, commercially available, platform independent, third party in-process quality monitoring system for metal additive manufacturing. it is available as a fully embedded oem installation or a stand-alone connection to your existing machines. additionally, sigma labs conducts contract metal 3d printing in materials inconnel718, 316 stainless, titanium, aluminum and ms1 tool steel. for more information please visit www.sigmalabsinc.com. for inquiries contact: sales@sigmalabsinc.com follow sigma labs on twi



What does NextTrip's logo look like?

NextTrip Inc. logo

Complete history of Ivan Gergel stock trades at Endo International plc, Nektar Therapeutics, and NextTrip

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
29 Sep 2017 Ivan P. Gergel
SVP Drug Development and CMO
Option 100,000 $11.04 $1,104,000
29 Sep 2017
98,279
16 Aug 2017 Ivan P. Gergel
SVP Drug Development and CMO
Sale 1,997 $19.32 $38,582
16 Aug 2017
41,575
18 Jul 2017 Ivan P. Gergel
SVP Drug Development and CMO
Option 54,920 $11.04 $606,317
18 Jul 2017
98,492
11 Jul 2017 Ivan P. Gergel
SVP Drug Development and CMO
Option 45,080 $11.04 $497,683
11 Jul 2017
80,263
16 May 2017 Ivan P. Gergel
SVP Drug Development and CMO
Sale 1,450 $19.55 $28,348
16 May 2017
43,572
16 Feb 2017 Ivan P. Gergel
SVP Drug Development and CMO
Sale 1,457 $13.14 $19,145
16 Feb 2017
45,022
16 Feb 2017 Ivan P. Gergel
SVP Drug Development and CMO
Sale 1,457 $13.14 $19,145
16 Feb 2017
45,022
16 Nov 2016 Ivan P. Gergel
SVP Drug Development and CMO
Sale 848 $13.96 $11,838
16 Nov 2016
26,479
16 Nov 2016 Ivan P. Gergel
SVP Drug Development and CMO
Sale 848 $13.96 $11,838
16 Nov 2016
26,479
16 Aug 2016 Ivan P. Gergel
SVP Drug Development and CMO
Sale 1,685 $17.56 $29,589
16 Aug 2016
27,327
16 Aug 2016 Ivan P. Gergel
SVP Drug Development and CMO
Sale 1,685 $17.56 $29,589
16 Aug 2016
27,327
16 May 2016 Ivan P. Gergel
SVP Drug Development and CMO
Option 1,250 $13.91 $17,388
16 May 2016
1,944
16 Feb 2016 Ivan P. Gergel
SVP Drug Development and CMO
Option 1,250 $11.54 $14,425
16 Feb 2016
1,250
10 Mar 2014 Ivan P. Gergel
EVP, R, D, and CSO
Option 75,637 $31.13 $2,354,580
10 Mar 2014
34,256


NextTrip executives and stock owners

NextTrip executives and other stock owners filed with the SEC include: